TY - JOUR
T1 - ACR Appropriateness Criteria® Staging of Renal Cell Carcinoma
T2 - 2022 Update
AU - Expert Panel on Urological Imaging
AU - Ganeshan, Dhakshinamoorthy
AU - Khatri, Gaurav
AU - Ali, Norman
AU - Avery, Ryan
AU - Caserta, Melanie P.
AU - Chang, Silvia D.
AU - De Leon, Alberto Diaz
AU - Gupta, Rajan T.
AU - Lyshchik, Andrej
AU - Michalski, Jeff
AU - Nicola, Refky
AU - Pierorazio, Phillip M.
AU - Purysko, Andrei S.
AU - Smith, Andrew D.
AU - Taffel, Myles T.
AU - Nikolaidis, Paul
N1 - Publisher Copyright:
Copyright © 2023 American College of Radiology. Published by Elsevier Inc. All rights reserved.
PY - 2023/5
Y1 - 2023/5
N2 - Renal cell carcinoma is a complex group of highly heterogenous renal tumors demonstrating variable biological behavior. Pretreatment imaging of renal cell carcinoma involves accurate assessment of the primary tumor, presence of nodal, and distant metastases. CT and MRI are the key imaging modalities used in the staging of renal cell carcinoma. Important imaging features that impact treatment include tumor extension into renal sinus and perinephric fat, involvement of pelvicalyceal system, infiltration into adrenal gland, involvement of renal vein and inferior vena cava, as well as the presence of metastatic adenopathy and distant metastases. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
AB - Renal cell carcinoma is a complex group of highly heterogenous renal tumors demonstrating variable biological behavior. Pretreatment imaging of renal cell carcinoma involves accurate assessment of the primary tumor, presence of nodal, and distant metastases. CT and MRI are the key imaging modalities used in the staging of renal cell carcinoma. Important imaging features that impact treatment include tumor extension into renal sinus and perinephric fat, involvement of pelvicalyceal system, infiltration into adrenal gland, involvement of renal vein and inferior vena cava, as well as the presence of metastatic adenopathy and distant metastases. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
KW - AUC
KW - Appropriate Use Criteria
KW - Appropriateness Criteria
KW - CT
KW - MRI
KW - Nephrectomy
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85160377691&partnerID=8YFLogxK
U2 - 10.1016/j.jacr.2023.02.008
DO - 10.1016/j.jacr.2023.02.008
M3 - Article
C2 - 37236747
AN - SCOPUS:85160377691
SN - 1546-1440
VL - 20
SP - S246-S264
JO - Journal of the American College of Radiology
JF - Journal of the American College of Radiology
IS - 5
ER -